# GilteRInf 2022 Study (Gilteritinib Related Infections)

> **NCT05791890** · — · UNKNOWN · sponsor: **University of Rome Tor Vergata** · enrollment: 78 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Gilteritinib

## Key facts

- **NCT ID:** NCT05791890
- **Lead sponsor:** University of Rome Tor Vergata
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-31
- **Primary completion:** 2024-05-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2023-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05791890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05791890, "GilteRInf 2022 Study (Gilteritinib Related Infections)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05791890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*